JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute Co., Ltd, has entered into a strategic partnership with Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Gilead’s subsidiary Kite Pharma. The collaboration aims to strengthen the industrialization process of bispecific CAR-T cell therapy, although financial details of the agreement were not disclosed.
JiCui Cell Therapy’s innovative BCMA/CD19 dual-targeted CAR-T cell therapy has demonstrated successful treatment outcomes in patients with gravis myasthenia, with the findings published in the reputable Journal of Neurology.- Flcube.com
